The Food and Drug Administration (FDA) has approved albumin-bound paclitaxel (nab-PTX) NPs as a primary treatment for advanced pancreatic cancer, and nab-PTX NPs show high treatment efficacy [4,5]. The gene discussed is ALB; the disease is familial pancreatic carcinoma.